Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1)

Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is a highly abundant neuronal enzyme (comprising up to 1–5% of total brain protein) primarily responsible for cleaving ubiquitin from small peptide substrates, thereby regulating the availability of free ubiquitin for the cell’s protein degradation machinery[1][3][4][5][7]. UCHL1 is a member of the peptidase C12 family and is classed as a deubiquitinating enzyme (DUB), with an additional proposed E3 ligase activity, though its hydrolytic function predominates[7][5]. It plays a vital role in neuronal function, particularly the maintenance of axonal and synaptic integrity, and has a structurally unusually complex, knotted catalytic core[1][4]. Dysregulation, mutation, or altered expression of UCHL1 is linked to neurodegenerative disorders (e.g., Parkinson's disease), several cancers, and is a validated biomarker for neuronal injury (notably in traumatic brain injury)[1][7][5]. While not essential for neuronal development, UCHL1's loss of function leads to progressive neuronal degeneration[1][7]. It is emerging as a therapeutic target in oncology and neurology, but therapeutic intervention must account for its indispensable roles in neuron survival and protein quality control[1][5][7][2].

Other names

UCH-L1PGP9.5Parkinson disease-associated protein 5 (PARK5)Neuron cytoplasmic protein 9.5Ubiquitin C-terminal hydrolase-1Ubiquitin thiolesterase L1HEL-117NDGOASPG79SPG79AEpididymis luminal protein 117UCHL-1

Inhibition of UCHL1 blocks deubiquitination, affecting protein turnover and potentially inducing cell death in cancer cells or modulating neurodegeneration